This CME Symposium takes place on Monday, September 15, 2014 from 6:30 PM - 8:30 PM at the Marriott Marquis Washington, DC in the Independence Ballroom, Salons A-E
PRLog - Aug. 12, 2014 - Click to Register Online
Oral Antiplatelet Therapies for Acute Coronary Syndromes: State-of-the-Art
Deepak Bhatt, MD, MPH (Chair)
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Paul Gurbel, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Robert Harrington, MD
Professor of Medicine
Stanford University School of Medicine
Stanford, California
Ajay Kirtane, MD
Assistant Professor of Clinical Medicine
Columbia University Medical Center
New York, New York
Manesh Patel, MD
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina
Marc Sabatine, MD, MPH
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Philippe Gabriel Steg, MD
Professor of Cardiology
Universite Paris-Diderot
Director, Coronary Care Unit
Hospital Bichat
Paris, France
Click to Register Online
Dual oral antiplatelet therapy, with aspirin and a P2Y12 receptor inhibitor, for the management of patients experiencing an acute coronary syndrome (ACS) has demonstrated significant improvements in the prevention of recurring major cardiovascular events versus aspirin alone. Clopidogrel, prasugrel, and ticagrelor are three P2Y12 receptor inhibitors, with unique pharmacologic properties, used in the management of ACS, and all three have been studied in large cardiovascular outcome clinical trials. Both prasugrel and ticagrelor have been evaluated separately against clopidogrel, on a background of aspirin therapy, in clinical trials with distinct designs and outcomes. In addition, after a myocardial infarction, another oral antiplatelet agent, vorapaxar, has been shown to be effective in reducing thrombotic cardiovascular events. Interventional cardiologists need to accurately assess risk and make prudent decisions on choice of antiplatelet therapy. Therefore, in this program, chair Dr. Deepak Bhatt and faculty members Dr. Philippe Gabriel Steg, Dr. Robert Harrington, Dr. Marc Sabatine, Dr. Ajay Kirtane, Dr. Paul Gurbel, and Dr. Manesh Patel will provide attendees with state-of-the-art information on these agents, interpret clinical trial data, and debate and recommend best treatment strategies in challenging ACS cases.
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP.
Pre-registration is for planning purposes only.
For additional CME activities and online cme courses visit CMEPlanet
Read Full Story - Oral Antiplatelet Therapies for Acute Coronary Syndromes: State-of-the-Art | More news from this source
Press release distribution by PRLog
Oral Antiplatelet Therapies for Acute Coronary Syndromes: State-of-the-Art
August 12, 2014 at 14:41 PM EDT
